EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieÄquivalenzstudieOpen Access

Platelet rich plasma injection for acute Achilles tendon rupture: PATH-2 randomised, placebo controlled, superiority trial

David J Keene iD, Joseph Alsousou, Paul Harrison, Philippa Hulley, Susan Wagland, Scott R Parsons, Jacqueline Y Thompson, Heather M O'Connor, Michael Maia Schlüssel, Susan J Dutton, Sarah E Lamb, Keith Willett und 1 weitere

BMJ · 20.11.2019 · l6132

DOI: 10.1136/bmj.l6132 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift BMJ, online erschienen am 20.11.2019. Verfasst von David J Keene und 12 weiteren Autor:innen. Beteiligte Einrichtung: Kadoorie Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK david.keen…. Hauptthemen laut MEDLINE: Platelet-Rich Plasma, Quality of Life. Die Arbeit wurde bisher 79-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Medical Research Council, Department of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To determine whether an injection of platelet rich plasma improves outcomes after acute Achilles tendon rupture.

Design

Randomised, placebo controlled, two arm, parallel group, participant and assessor masked, superiority trial.

Setting

Secondary care trauma units across 19 hospitals in the United Kingdom’s health service.

Participants

Recruitment commenced in July 2015 and follow-up was completed in March 2018. 230 adults aged 18 years and over were included, with acute Achilles tendon rupture presenting within 12 days of injury and managed with non-surgical treatment. Exclusions were injury at the insertion or musculotendinous junction, major leg injury or deformity, diabetes mellitus, platelet or haematological disorder, systemic corticosteroids, anticoagulation treatment, and other contraindicating conditions.

Interventions

Participants were randomised 1:1 to platelet rich plasma (n=114) or placebo (dry needle; n=116) injection. All participants received standard rehabilitation care (ankle immobilisation followed by physiotherapy). Main outcomes and measures Primary outcome was muscle tendon function at 24 weeks, measured objectively with the limb symmetry index (injured/uninjured×100) in maximal work done during the heel rise endurance test (an instrumented measure of repeated single leg heel rises until fatigue). Secondary outcomes included patient reported function (Achilles tendon rupture score), quality of life (short form 12 version 2®), pain (visual analogue scale), goal attainment (patient specific functional scale), and adverse events. A central laboratory analysed the quality and content of platelet rich plasma. Analyses were by modified intention to treat.

Results

Participants were 46 years old on average, and 57 (25%) of 230 were female. At 24 weeks, 202 (88%) participants completed the heel rise endurance test and 216 (94%) the patient reported outcomes. The platelet rich plasma was of good quality, with expected growth factor content. No difference was detected in muscle tendon function between participants receiving platelet rich plasma injections and those receiving placebo injections (limb symmetry index, mean 34.7% (standard deviation 17.7%) v 38.5% (22.8%); adjusted mean difference −3.9% (95% confidence interval −10.5% to 2.7%)) or in any secondary outcomes or adverse event rates. Complier average causal effect analyses gave similar findings.

Conclusions

There is no evidence to indicate that injections of platelet rich plasma can improve objective muscle tendon function, patient reported function, or quality of life after acute Achilles tendon rupture compared with placebo, or that they offer any patient benefit.

Trial registration

ISRCTN54992179.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Platelet-Rich PlasmaQuality of LifeAchilles TendonAdultConservative TreatmentFemaleHumansInjectionsMaleMiddle AgedPatient Reported Outcome MeasuresRecovery of FunctionTendon InjuriesTreatment OutcomeUnited Kingdom

Autor:innen und Institutionen

  • Kadoorie Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK david.keene@ndorms.ox.ac.uk.
  • Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
  • Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.
  • Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
  • Kadoorie Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
  • Oxford Clinical Trials Research Unit, Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.

ORCID-Profile: David J Keene

Förderung

  • Medical Research Council
  • Department of Health

Zitieren

APA

Keene, D. J., Alsousou, J., Harrison, P., Hulley, P., Wagland, S., Parsons, S. R., Thompson, J. Y., O'Connor, H. M., Schlüssel, M. M., Dutton, S. J., Lamb, S. E., Willett, K., & PATH-2 trial group (2019). Platelet rich plasma injection for acute Achilles tendon rupture: PATH-2 randomised, placebo controlled, superiority trial. BMJ, l6132. https://doi.org/10.1136/bmj.l6132

Vancouver

Keene DJ, Alsousou J, Harrison P, Hulley P, Wagland S, Parsons SR, et al. Platelet rich plasma injection for acute Achilles tendon rupture: PATH-2 randomised, placebo controlled, superiority trial. BMJ. 2019:l6132. doi:10.1136/bmj.l6132

BibTeX
@article{Keene2019,
  author = {Keene, David J and Alsousou, Joseph and Harrison, Paul and Hulley, Philippa and Wagland, Susan and Parsons, Scott R and Thompson, Jacqueline Y and O'Connor, Heather M and Schlüssel, Michael Maia and Dutton, Susan J and Lamb, Sarah E and Willett, Keith and PATH-2 trial group, PATH-2 trial group},
  title = {Platelet rich plasma injection for acute Achilles tendon rupture: PATH-2 randomised, placebo controlled, superiority trial},
  journal = {BMJ},
  year = {2019},
  pages = {l6132},
  doi = {10.1136/bmj.l6132}
}
Kostenlos starten →